Organon to acquire Dermavant from Roivant for $1.2bn.

Organon, a healthcare company, agreed to acquire Dermavant, a Roivant company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology, from Roivant, a biotech company, for $1.2bn. “We look forward to combining Dermavant’s strong dermatology commercial and field medical organization in the US, with Organon’s market access capabilities, regulatory expertise and worldwide commercial reach. This will allow us to bring VTAMA cream, a patient-focused innovation in dermatology, providing an effective, well-tolerated, non-steroidal treatment option to the millions of people living with plaque psoriasis and potentially atopic dermatitis. The acquisition will deliver on Organon’s objective of improving the health of women throughout their life stages by investing in treatments for conditions that affect women differently,” Kevin Ali, Organon Chief Executive Officer.